STOCK TITAN
  1. Home
  2. Sec-filings
  3. KNSA
  4. [Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity

Kiniksa COO reports option exercise and share sales under 10b5-1

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals (KNSA) reported a Form 4 for its COO. On 10/14/2025, the officer exercised 6,500 options at $8.83 and sold 11,815 shares at a $37.65 weighted average and 553 shares at $37.99, executed through multiple trades under a Rule 10b5-1 plan adopted on April 29, 2024. Following these transactions, the officer beneficially owned 28,684 Class A shares directly and 12,500 options remained held. The reported option was fully vested and exercisable.

Positive

  • None.

Negative

  • None.
Insider Tessari Eben
Role CHIEF OPERATING OFFICER
Sold 12,368 shs ($466K)
Type Security Shares Price Value
Exercise Share Option 6,500 $0.00 --
Exercise Class A Ordinary Share 6,500 $8.83 $57K
Sale Class A Ordinary Share 11,815 $37.65 $445K
Sale Class A Ordinary Share 553 $37.99 $21K
Holdings After Transaction: Share Option — 12,500 shares (Direct); Class A Ordinary Share — 41,052 shares (Direct)
Footnotes (1)
  1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $36.98 and $37.97. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $37.98 and $38.00. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. The option is fully vested and exercisable.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tessari Eben
(Last) (First) (Middle)
23 OLD BOND STREET, THIRD FLOOR
(Street)
LONDON X0 W1S 4PZ
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF OPERATING OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
10/14/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Ordinary Share 10/14/2025 M(1) 6,500 A $8.83 41,052 D
Class A Ordinary Share 10/14/2025 S(1) 11,815 D $37.65(2) 29,237 D
Class A Ordinary Share 10/14/2025 S(1) 553 D $37.99(3) 28,684 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Share Option $8.83 10/14/2025 M(1) 6,500 (4) 09/16/2029 Class A Ordinary Share 6,500 $0 12,500 D
Explanation of Responses:
1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.
2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $36.98 and $37.97. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $37.98 and $38.00. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
4. The option is fully vested and exercisable.
/s/ Douglas Barry, Attorney-in-Fact 10/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did KNSA’s COO report on Form 4?

The COO exercised 6,500 options at $8.83 and sold 11,815 shares at $37.65 (weighted average) and 553 shares at $37.99 on 10/14/2025.

Was the KNSA insider trading under a 10b5-1 plan?

Yes. The transactions were made under a Rule 10b5-1 plan executed on April 29, 2024.

What are the COO’s holdings after the transactions?

Direct beneficial ownership is 28,684 Class A shares, with 12,500 options remaining.

What were the sale prices reported?

Sales were reported at weighted average prices of $37.65 and $37.99, each executed through multiple trades.

Were the options fully vested at exercise?

Yes. The filing states the option is fully vested and exercisable.

What was the transaction date on the Form 4 for KNSA?

The transactions occurred on 10/14/2025.